A5037977551- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Hemoglobinopathies and Related Disorders
- Immune Cell Function and Interaction
- Epigenetics and DNA Methylation
- Autoimmune and Inflammatory Disorders Research
- Bone and Joint Diseases
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Cardiovascular Function and Risk Factors
- Immune cells in cancer
- Cancer-related gene regulation
- Advanced MRI Techniques and Applications
- Hemophilia Treatment and Research
- CAR-T cell therapy research
- Mesenchymal stem cell research
- Eosinophilic Disorders and Syndromes
- CNS Lymphoma Diagnosis and Treatment
Hospital Del Mar
2022-2025
Instituto de Investigación Biomédica de Salamanca
2016-2024
Complejo Hospitalario de Salamanca
2016-2024
Hebron University
2024
Vall d'Hebron Hospital Universitari
2024
Universidad de Salamanca
2015-2023
Hospital del Mar Research Institute
2022
Parc de Salut
2022
Centro de Investigación del Cáncer
2020
Boston University
2019
Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis, with increased incidence in older individuals. Here we analyze the transcriptome of human HSCs purified from young and healthy adults, as well MDS patients, identifying transcriptional alterations following different patterns expression. While aging-associated lesions seem to predispose myeloid transformation, disease-specific may trigger development. Among MDS-specific...
Abstract Background High-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell transplantation (allo-SCT). most frequent pre-allo-SCT monotherapy hypomethylating agents (HMA), but approximately 40% of patients cannot proceed to allo-SCT, mainly due disease progression. Recent evidence suggests that combining HMA venetoclax (HMA/VEN) could...
Myelodysplastic syndromes (MDS) are hematological disorders at high risk of progression to secondary acute myeloid leukemia (sAML). However, the mutational dynamics and clonal evolution underlying disease poorly understood present. To elucidate pathways genes occurring during sAML, next generation sequencing was performed on 84 serially paired samples MDS patients who developed sAML (discovery cohort) 14 from did not progress follow-up (control cohort). Results were validated in an...
Summary Patients with low‐risk myelodysplastic syndromes (MDS) usually develop iron overload. This leads to a high level of oxidative stress in the bone marrow (BM) and increases haematopoietic cell dysfunction. Our objective was analyse whether chelation deferasirox (DFX) alleviates consequences improves BM functionality. We analysed 13 iron‐overloaded MDS patients' samples before 4–10 months after treatment DFX. Using multiparametric flow cytometry analysis, we measured intracellular...
Background. Immunotherapy represents one of the fundamental treatments in management some types cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest multiple organs and systems. We present a case hematological toxicity, manifested as hemophagocytic syndrome (HPS), which was successfully treated with an anti-interleukin-6 antibody (tocilizumab). Case Report. This presents 75-year-old woman diagnosed metastatic choroidal melanoma,...
Summary Treatment with azacitidine ( AZA ) has been suggested to be of benefit for higher‐risk myelodysplastic syndrome HR ‐ MDS patients chromosome 7 abnormalities (Abn 7). This retrospective study 235 Abn treated n = 115) versus best supportive care BSC ; 120), assessed treatment as a time‐varying variable in multivariable analysis. A Cox Regression model time‐interaction terms overall survival OS at different time points confirmed that, while cytogenetic categories (complex karyotype [ CK...
Abstract Introduction Diagnosis of myelodysplastic syndromes ( MDS s) when anemia is the only abnormality can be complicated. The aim our study was to investigate primary causes and/or macrocytosis uncertain etiology. Methods We conducted a multicenter, prospective over 4 months in three hematology laboratories. In step 1, we used an automated informatics system screen 137 453 hemograms for cases (n = 2702). 2, excluded all patients whose appeared due known cause. This left 290 had 3,...
Background: Acquired hemophilia A (AHA) is a rare bleeding disease caused by autoantibodies against factor VIII. Spontaneous symptoms usually affect the skin and muscle, while pericardial effusion an extremely manifestation. In elderly, anticoagulant treatment frequent are associated with this. Clinical findings: We report hemorrhagic as AHA debut in patient untreated chronic lymphocytic leukemia anticoagulated apixaban for atrial fibrillation arterial ischemia. The was treated recombinant...
Summary Cardiovascular disease (CVD) involves the second cause of death in low‐risk myelodysplastic syndrome (MDS) population. Prospective study to characterise CVD and identify predictors for combined event (CE) cardiovascular and/or all‐cause mortality transfusion dependent MDS patients. Thirty‐one patients underwent a cardiac assessment including biomarkers magnetic resonance (cMR) with parametric sequences (T1, T2 T2* mapping) myocardial deformation by feature tracking (FT) were analysed...
Primary cutaneous plasmacytoma should be in the differential diagnosis case of solitary or multiple erythematous–violaceous nodules papules. The relies on clinical, histological, and immunochemical findings, without underlying evidence myeloma. Treatment individualized, agents such as bortezomib lenalidomide have shown to effective. Multiple myeloma (MM) is a malignant hematological disease characterized by proliferation clonal plasma cells bone marrow with monoclonal immunoglobulin...
<title>Abstract</title> Lenalidomide (LEN) can induce RBC transfusion independence (RBC-TI) in 60–70% of del(5q) myelodysplastic syndrome (MDS) patients. Current recommendation is to continue LEN responding patients until failure or progression, with likelihood toxicity and a high cost for healthcare systems. This HARMONY Alliance study investigated the outcome MDS who discontinued RBC-TI. We enrolled 118 an IPSS-R low-intermediate risk. Seventy (59%) intolerance, 38 (32%) per their...